| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.9M | — | — |
| Cost of Revenue | $1.7M | — | — |
| R&D Expense | $186K | — | -4.3% |
| SG&A Expense | $21.1M | — | +1186.8% |
| Operating Income | -$13.1M | — | -613.6% |
| Pre-tax Income | -$10.2M | — | -420.3% |
| Income Tax | $0 | — | — |
| Net Income | -$10.2M | — | -420.3% |
| EPS (Basic) | -$3.09 | — | -865.6% |
| EPS (Diluted) | -$3.09 | — | -865.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.0M | +77.9% | — |
| Accounts Receivable | $11.7M | +32.1% | — |
| Inventory | $23.4M | -0.7% | — |
| Current Assets | $69.8M | +30.7% | +7560.5% |
| Total Assets | $145.4M | +11.5% | — |
| Current Liabilities | $25.0M | -3.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.1M | — | -1976.5% |
| Capital Expenditures | $194K | — | — |
| Investing Cash Flow | -$194K | — | — |
| Financing Cash Flow | $27.5M | — | — |
| Free Cash Flow | -$13.3M | — | -2007.2% |
| +389.6% |
| Total Liabilities | $110.3M | +20.5% | +2059.3% |
| Stockholders' Equity | $35.1M | -9.7% | +936.6% |